ALLR News and Press, Allarity Therapeutics Inc. From 01/23/23

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Allarity Therapeutics (NASDAQ: ALLR ) stock is rising higher on Monday after signing an amended letter agreement with 3i . 3i is a holder of Series A Convertible Preferred Stock and the let...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com We’re starting off the week with a breakdown of the biggest pre-market stock movers for Monday! Moving stocks this morning are filings, clinical trial data, and more. Let&...

Press release Boston, MA U.S.A. (January 20, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® companion diagnostics ...

PRESS RELEASE Boston , MA U.S.A. ( December 1 , 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® ...

Allarity Therapeutics press release ( NASDAQ: ALLR ): Q3 Net loss was $5.0 million for the three months ended September 30, 2022, compared to $1.4 million for the comparable period in 2021. For further details see: Allarity Therapeutics reports Q3 results

Press release Cambridge, MA U.S.A. (November 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® companion ...

Press release Cambridge, MA U.S.A. (November 7, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagno...

(NewsDirect) Once brought into its pipeline , Allarity uses its DRP® platform to develop companion diagnostics alongside each drug to improve the treatments in a personalized medicine approach. Earlier this year, the company refocused its pipeline strategy toward co...

--News Direct-- Once brought into its pipeline , Allarity uses its DRP® platform to develop companion diagnostics alongside each drug to improve the treatments in a personalized medicine approach. Earlier this year, the company refocused its pipeline strategy toward...

Allarity Therapeutics press release ( NASDAQ: ALLR ): Q2 GAAP EPS of -$0.72 misses by $0.46 . As of June 30, 2022, Allarity’s cash was $7.7 million, as compared to $19.6 million as of December 31, 2021 Shares +4.07% . For further details see: A...